New York, May 29, 2026, 07:04 EDT
iSpecimen Inc. was down in quiet pre-market action Friday, hovering close to its lows after a reverse stock split. Investors waited for the next shareholder meeting and kept an eye on the company’s soft cash and revenue numbers as the biospecimen marketplace worked to steady itself.
iSpecimen is pushing ahead with its 2025 annual meeting, according to a recent regulatory filing. The meeting, delayed multiple times for lack of quorum, is now scheduled to pick up again May 29 at 9:00 a.m. Eastern. The company said none of the proposals up for a vote have changed.
Nasdaq trades regular hours from 9:30 a.m. to 4:00 p.m. ET. Pre-market is open from 4:00 a.m. to 9:30 a.m. ET. According to the 2026 holiday schedule, the U.S. equity market was shut for Memorial Day on May 25, and the next closure is set for Juneteenth, June 19.
ISPC slipped about 1.1% in pre-market to $3.284 after closing near $3.32. With 1,437,157 shares outstanding as of May 15, the equity is valued at roughly $4.8 million.
ISPC shares don’t have much cushion. TradingView put the stock 33.6% lower for the month and off 92.6% for the past year. Shares fell to a record low of $3.20 on May 20.
Investors are watching a financing move from earlier this month. iSpecimen raised about $2.5 million in gross proceeds through a private placement, selling common stock at $5.12 a share and pre-funded warrants. The warrants let buyers get almost all the way to owning stock, with most of the price paid up front. iSpecimen said it would use the funds for working capital, with up to $900,000 marked for marketing.
The cash gave iSpecimen some breathing room, but didn’t ease the squeeze last quarter. For the quarter ended March 31, iSpecimen posted revenue of $156,009, down from $1.06 million a year ago. Net loss widened to $2.28 million from $1.66 million.
The company reported its cash and cash equivalents dropped to roughly $2.82 million as of March 31, down from $6.88 million at the end of December. Management said there is “substantial doubt” about its ability to keep running as a going concern, meaning it may need to improve its finances or find more capital to stay in business. SEC
Nasdaq has told iSpecimen the stock is back in line with the $1 minimum bid requirement. iSpecimen said it got the notice from Nasdaq on May 12, after shares closed at or above $1 for ten business days, from April 28 through May 11. That minimum bid rule means shares must close at $1 or more to stay listed on Nasdaq.
The 1-for-40 reverse stock split is now recorded in the latest quarterly filing. Reverse splits reduce share count and increase the price per share but leave the overall company value the same.
Competition is a factor. iSpecimen calls the biospecimen procurement field fragmented and points to Discovery Life Sciences, StemExpress and Science Exchange as other specimen suppliers or research services platforms. The company says its tech-driven marketplace stands apart, but first-quarter numbers came in weak with both customer orders and specimen sales down.
ISPC dropped even though the wider market stayed positive. Nasdaq was at 26,917.47, up 0.91%, and the S&P 500 gained 0.58% to 7,563.63, according to Investing.com. iSpecimen moved on its own concerns over capital, revenue, and shareholder sign-offs.
The outlook shifts if the meeting gets quorum, shareholders give the green light, and management can prove marketing and platform spending is driving orders. The risks are also out there: if revenue stays soft or votes don’t go through, iSpecimen may have to raise more cash, which could dilute current holders — existing shareholders would be left with a smaller stake in the company.
The next signals are Friday’s reconvened meeting results, any proxy or registration update connected to the private placement, and whether trading volume changes after the Nasdaq opens for regular trading.
